Reelin deficiency exacerbates cocaine‐induced hyperlocomotion by enhancing neuronal activity in the dorsomedial striatum
Genes, Brain and Behavior · 2022-09 · 21 (7)
DOI: 10.1111/gbb.12828 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Brain and Behavior, online erschienen am 29.07.2022. Verfasst von Giordano de Guglielmo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Cocaine. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
The Reln gene encodes for the extracellular glycoprotein Reelin, which regulates several brain functions from development to adulthood, including neuronal migration, dendritic growth and branching and synapse formation and plasticity. Human studies have implicated Reelin signaling in several neurodevelopmental and psychiatric disorders. Mouse studies using the heterozygous Reeler (HR) mice have shown that reduced levels of Reln expression are associated with deficits in learning and memory and increased disinhibition. Although these traits are relevant to substance use disorders, the role of Reelin in cellular and behavioral responses to addictive drugs remains largely unknown. Here, we compared HR mice to wild‐type (WT) littermate controls to investigate whether Reelin signaling contributes to the hyperlocomotor and rewarding effects of cocaine. After a single or repeated cocaine injections, HR mice showed enhanced cocaine‐induced locomotor activity compared with WT controls. This effect persisted after withdrawal. In contrast, Reelin deficiency did not induce cocaine sensitization, and did not affect the rewarding effects of cocaine measured in the conditioned place preference assay. The elevated cocaine‐induced hyperlocomotion in HR mice was associated with increased protein Fos expression in the dorsal medial striatum (DMS) compared with WT. Lastly, we performed an RNA fluorescent in situ hybridization experiment and found that Reln was highly co‐expressed with the Drd1 gene, which encodes for the dopamine receptor D1, in the DMS. These findings show that Reelin signaling contributes to the locomotor effects of cocaine and improve our understanding of the neurobiological mechanisms underlying the cellular and behavioral effects of cocaine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.
- Department of Medicine, University of California, San Diego, La Jolla, California, USA.
- Animal Models Core Facility, The Scripps Research Institute, La Jolla, California, USA.
ORCID-Profile: Giordano de Guglielmo, Francesca Telese
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
de Guglielmo, G., Iemolo, A., Nur, A., Turner, A., Montilla-Perez, P., Martinez, A., Crook, C., Roberts, A., & Telese, F. (2022). Reelin deficiency exacerbates cocaine‐induced hyperlocomotion by enhancing neuronal activity in the dorsomedial striatum. Genes, Brain and Behavior, 21(7). https://doi.org/10.1111/gbb.12828
Vancouver
de Guglielmo G, Iemolo A, Nur A, Turner A, Montilla-Perez P, Martinez A, et al. Reelin deficiency exacerbates cocaine‐induced hyperlocomotion by enhancing neuronal activity in the dorsomedial striatum. Genes, Brain and Behavior. 2022;21(7). doi:10.1111/gbb.12828
BibTeX
@article{deGuglielmo2022,
author = {de Guglielmo, Giordano and Iemolo, Attilio and Nur, Aisha and Turner, Andrew and Montilla-Perez, Patricia and Martinez, Angelica and Crook, Caitlin and Roberts, Amanda and Telese, Francesca},
title = {Reelin deficiency exacerbates cocaine‐induced hyperlocomotion by enhancing neuronal activity in the dorsomedial striatum},
journal = {Genes, Brain and Behavior},
year = {2022},
volume = {21},
number = {7},
doi = {10.1111/gbb.12828}
}
EUVIMED